

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

***APPLICATION NUMBER:***

**74285**

**APPROVAL LETTER**

ANDA 74-285

MAY 7 1996

Purepac Pharmaceutical Co.  
Attention: Joan Janulis  
200 Elmora Avenue  
Elizabeth, NJ 07207

Dear Madam:

This is in reference to your abbreviated new drug application dated December 11, 1992, submitted pursuant to Section 505(j) of the Federal Food, Drug, and Cosmetic Act, for Diflunisal Tablets USP, 250 mg and 500 mg.

Reference is also made to your amendments dated March 29 and April 17, 1996.

We have completed the review of this abbreviated application and have concluded that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly, the application is approved. The Division of Bioequivalence has determined your Diflunisal Tablets USP, 250 mg and 500 mg to be bioequivalent and, therefore, therapeutically equivalent to the listed drug (Dolobid® 250 mg and 500 mg of Merck and Co., Inc.). Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

Under 21 CFR 314.70, certain changes in the conditions described in this abbreviated application require an approved supplemental application before the change may be made.

Post-marketing reporting requirements for this abbreviated application are set forth in 21 CFR 314.80-81. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

We request that you submit, in duplicate, any proposed advertising or promotional copy which you intend to use in your initial advertising or promotional campaigns. Please submit all proposed materials in draft or mock-up form, not final print. Submit both copies together with a copy of the proposed or final printed labeling to the Division of Drug Marketing, Advertising, and Communications (HFD-240). Please do not use Form FD-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) for this initial submission.

We call your attention to 21 CFR 314.81(b)(3) which requires that materials for any subsequent advertising or promotional campaign be submitted to our Division of Drug Marketing, Advertising, and Communications (HFD-240) with a completed Form FD-2253 at the time of their initial use.

Sincerely yours,

/S/

5/7/96

Douglas L. Spohn  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research

cc: ANDA 74-285  
Division File  
Field Copy  
HFD-600/Reading File  
HFD-82  
HFD-8/P.Savino  
HFD-610/J.Phillips

Endorsements:

HFD-623/J.Clark/4-12-96 *J. Clark 4-30-96*  
HFD-623/V.Sayeed, Ph.D./4-23-96 *Vilayat A Sayeed 4/30/96*  
HFD-613/C.Hoppes/4-24-96 *C. Hoppes 4/30/96*  
HFD-617/J.Wilson/CSO/4-22-96 *James Wilson 4/30/96*  
X:\NEW\FIRMSNZ\PUREPAC\LRS&REV 74285AP.CL  
F/T by: bc/4-22-96

APPROVAL

*[Signature]* 5/7/96

*J. Phillips 5/7/96*